Mirena in Idiopathic Menorrhagia

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: March 23, 2009
Last updated: April 12, 2010
Last verified: April 2010

This is an open-label, uncontrolled, multi-centre observational study that analyses a follow-up of 1600 women with dysfunctional uterine bleeding (idiopathic menorrhagia) over a period of one year.The patients evaluated at four visits, beginning with the insertion visit and 3, 6 and 12 months after insertion.

Condition Intervention Phase
Idiopathic Menorrhagia
Drug: Levonorgestrel IUS (Mirena , BAY86-5028)
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Levonorgestrel Releasing Intrauterine Device (Mirena) in Idiopathic Menorrhagia

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • To evaluate the improvement in the quality of life and the degree of satisfaction of women with idiopathic menorrhagia treated with Mirena [ Time Frame: At vist 1 and 4 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Information about the pattern of menstrual bleeding recorded in an ongoing way throughout the duration of the study [ Time Frame: Every visit ] [ Designated as safety issue: No ]
  • The health-related quality of life questionnaire SF-36 at Visits 1 and 4 [ Time Frame: Visit 1 and 4 ] [ Designated as safety issue: No ]
  • The user satisfaction as recorded at Visit 4 [ Time Frame: visit 4 ] [ Designated as safety issue: No ]
  • Adverse reactions recorded in an ongoing way throughout the duration of the study [ Time Frame: every visit ] [ Designated as safety issue: Yes ]
  • Laboratory parameters as measured at Visits 1 and 4 [ Time Frame: visit 1 and 4 ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   None Retained


Enrollment: 1000
Study Start Date: August 2004
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: Levonorgestrel IUS (Mirena , BAY86-5028)
One group


Ages Eligible for Study:   30 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Women diagnosed with idiopathic menorrhagia, age 30-45, BMI 18-34


Inclusion Criteria:

  • Woman diagnosed with idiopathic Menorrhagia according to assessment of the investigator and according to international guidelines. These woman should also accept to be on contraception during the time period that they have Mirena in situ.
  • Age limit 30-45
  • BMI= 18-34
  • Signed informed consent

Exclusion Criteria:

  • Medical conditions featured in the Mirena data sheet (See Appendix 1) that contraindicate its use, listed below:
  • Known or suspected pregnancy; current or recurrent pelvic inflammatory disease; infection of the lower genital tract; postpartum endometritis; septic abortion during the past three months; cervicitis; cervical dysplasia; uterine or cervical malignancy; undiagnosed abnormal uterine bleeding; congenital or acquired abnormality of the uterus including fibroids if they distort the uterine cavity; conditions associated with increased susceptibility to infections; acute liver disease or liver tumor; known hypersensitivity to any of the constituents of the product.
  • Nulliparity
  • Consumption of Iron, Antiprostaglandins, hormonal drugs and any medication that could effect bleeding should be stopped at least 3 months before the first visit and should not be used during the course of the study.
  • History of diabetes mellitus,cardiovascular disease and thyroid abnormalities
  • Anticoagulation therapy
  • Cancer history including breast cancer.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00868153

Many Locations, Bulgaria
Many Locations, Croatia
Many Locations, India
Many Locations, Jordan
Many Locations, Kuwait
Many Locations, Pakistan
Many Locations, Romania
Russian Federation
Many Locations, Russian Federation
Saudi Arabia
Many Locations, Saudi Arabia
Many Locations, Serbia
Sri Lanka
Many Locations, Sri Lanka
Many Locations, Turkey
United Arab Emirates
Many Locations, United Arab Emirates
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided

Responsible Party: Medical Affairs Therapeutic Area Head, Bayer Schering Pharma AG
ClinicalTrials.gov Identifier: NCT00868153     History of Changes
Other Study ID Numbers: 14494, MA0501
Study First Received: March 23, 2009
Last Updated: April 12, 2010
Health Authority: Bulgaria: Bulgarian Drug Agency
Croatia: Agency for Medicinal Product and Medical Devices
Croatia: Ethics Committee
India: Ministry of Health
Jordan: Ethical Committee
Pakistan: Ministry of Health
Romania: National Ethics Committee
Romania: National Medicines Agency
Russia: Ethics Committee
Russia: Ministry of Health of the Russian Federation
Serbia: Ethics Committee
Serbia and Montenegro: Agency for Drugs and Medicinal Devices
Turkey: Ethics Committee
Turkey: Ministry of Health

Additional relevant MeSH terms:
Uterine Hemorrhage
Uterine Diseases
Genital Diseases, Female
Menstruation Disturbances
Pathologic Processes
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Contraceptives, Oral, Synthetic
Contraceptives, Oral

ClinicalTrials.gov processed this record on October 19, 2014